Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
MONROVIA, Calif. --(BUSINESS WIRE)--Jun. 22, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb ® 2+1
View HTML
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. --(BUSINESS WIRE)--May 26, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
View HTML
Toggle Summary Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
MONROVIA, Calif. --(BUSINESS WIRE)--May 15, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb ® 2+1
View HTML
Toggle Summary Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
-- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested -- -- Robust, dose-dependent immune activation consistent with inhibition of both PD-1 and CTLA-4 checkpoints -- -- Further dose-escalation and expansion cohorts continue to enroll
View HTML
Toggle Summary Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
MONROVIA, Calif. --(BUSINESS WIRE)--May 13, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
View HTML
Toggle Summary Xencor Reports First Quarter 2020 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 7, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported
View HTML
Toggle Summary Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 30, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after
View HTML
Toggle Summary Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 25, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered into a technology license agreement with Vir
View HTML
Toggle Summary Xencor Reports Fourth Quarter and Full Year 2019 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported
View HTML
Toggle Summary Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 18, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2019
View HTML